Tata Chemicals Q3 FY26 Results: Consolidated Loss of ₹69 Crore, Standalone Profit of ₹73 Crore
Tata Chemicals reported a consolidated loss of ₹69 crore for Q3 FY26, down from a profit of ₹154 crore in Q3 FY25. Standalone profit was ₹73 crore, up from ₹72 crore. Consolidated revenue was ₹3,550 crore, and standalone revenue was ₹1,204 crore for the quarter ended December 31, 2025.
Quarterly results, especially a shift from profit to loss on a consolidated basis, can impact investor sentiment and stock price. The standalone performance is stable but not significantly positive.
The consolidated results show a decline in profitability with a loss, while standalone results show a marginal increase. The mixed performance leads to a neutral sentiment.
Tata Chemicals Limited announced its Unaudited Consolidated and Audited Standalone Financial Results for the third quarter and nine months ended December 31, 2025. The Board of Directors approved these results in a meeting held on February 2, 2026. The consolidated results for the quarter ended December 31, 2025, reported a loss of ₹69 crore, a significant shift from the profit of ₹154 crore in the same period last year. Revenue from continuing operations for the consolidated entity stood at ₹3,550 crore, compared to ₹3,590 crore in the prior year's quarter.
On a standalone basis, the company reported a profit after tax of ₹73 crore for the quarter ended December 31, 2025. This marks an increase from ₹72 crore in the corresponding quarter of the previous year. Standalone revenue from continuing operations was ₹1,204 crore, up from ₹1,166 crore in the third quarter of FY25.
The company also published these financial results in the Business Standard (English), The Free Press Journal (English), and Navshakti (Marathi) newspapers on February 3, 2026. The full financial results are available on the company's website, www.tatachemicals.com, and the stock exchanges' websites.
What to do with a filing like this
Tata Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Tata Chemicals Limited. Read the original for the full detail.